Austrianova
Austrianova is a Singapore-headquartered B2B biotechnology company that develops proprietary cell-encapsulation platforms (Cell-in-a-Box® for mammalian cells, Bac-in-a-Box® for bacteria/yeast) and provides GMP4Cells manufacturing services to pharmaceutical, biotech, cosmeceutical, agricultural, and academic partners globally.
- Company typePrivate
- Founded2014
- HeadquartersVienna, Austria
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Austrianova does
Austrianova (legal entity: SGAustria Pte. Ltd.) is a Singapore-headquartered biotechnology company that develops and commercializes proprietary cell-encapsulation platforms — Cell-in-a-Box® for mammalian (human and animal) cells and Bac-in-a-Box® for bacteria and yeast — using porous cellulose sulphate polymer capsules (and the Gel8 cotton-derived polymer for the bacterial variant). The Cell-in-a-Box® capsule protects implanted cells from immune rejection while permitting diffusion of nutrients, waste, and biologically synthesized molecules; Bac-in-a-Box® provides stomach-acid protection and ambient-temperature storage, claimed at 10,000x better acid protection than competing technologies. The company supports these platforms with a GMP-compliant manufacturing stack (GMP4Cells) offering Master Cell Bank and Working Cell Bank production, Fill and Finish, cell-line development (including a λ-Integrase transgenesis platform for stable producer cell lines), stem cell manufacturing, Pep-in-a-Box® enzyme encapsulation, and in-house sterility/mycoplasma/endotoxin testing. Manufacturing is performed at a Thai-FDA-licensed, ISO 9001:2015-certified facility at Thailand Science Park with annual capacity measured in thousands of syringes/vials per campaign, and the technology is the subject of a US FDA Drug Master File already cross-referenced in PharmaCyte's pancreatic-cancer IND.
Austrianova operates a B2B, project- and contract-based commercial model with three reinforcing revenue streams: (i) contract manufacturing and R&D services paid via project fees and milestone payments; (ii) licensing of Cell-in-a-Box® and Bac-in-a-Box® IP to partners, generating upfront fees, development/regulatory milestones, and royalties on net sales; and (iii) co-development partnerships where Austrianova contributes technology and manufacturing in exchange for development funding and future commercial payments. Customers and partners span pharmaceutical and biotech companies (Avaí Bio via the Klothonova 50/50 JV; PharmaCyte Biotech; Kingen Biotech), cosmeceuticals (L'Oreal), agriculture/livestock (ProAgni for methane-reducing cattle-feed additives), and academic medicine (San Raffaele University and Research Hospital for multiple myeloma; University of Veterinary Medicine Vienna for cancer encapsulated-cell studies). The company has 11–50 employees and offices in Singapore (HQ plus Bac-in-a-Box® R&D), Thailand (GMP manufacturing), and Germany (Munich/Martinsried subsidiary). It is privately held, previously operating as SG Austria, and has received preferred equity investment from Checkmate Capital Group, whose CEO was appointed to the board in April 2026.
Austrianova firmographics
Firmographics- Name
- Austrianova
- Legal name
- SGAustria Pte. Ltd.
- Website
- https://austrianova.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Austrianova is a Singapore-headquartered B2B biotechnology company that develops proprietary cell-encapsulation platforms (Cell-in-a-Box® for mammalian cells, Bac-in-a-Box® for bacteria/yeast) and provides GMP4Cells manufacturing services to pharmaceutical, biotech, cosmeceutical, agricultural, and academic partners globally.
- Ownership category
- akta.pro rank
Austrianova industry classification
Industry- Product category
- Cell Encapsulation & GMP Cell Manufacturing Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industries
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Culture Carriers & Encapsulation Systems (Cryoprotectants, Microencapsulation, Delivery Matrices) (AFAJAJAK)
Keywords
Where Austrianova is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Offices3 records
Markets served
Austrianova business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- B2B Contract Manufacturing Services: Austrianova provides GMP cell banking, cell line development, and encapsulated cell manufacturing services to pharmaceutical, biotech, and life sciences companies on a project contract basis. Services include Master Cell Bank and Working Cell Bank production, Fill and Finish, and R&D services. Revenue is generated through project fees, milestone payments, and service contracts.
- Licensing and Technology Royalties: Austrianova licenses its Cell-in-a-Box® and Bac-in-a-Box® encapsulation technologies to partners for development and commercialization of therapeutic and commercial products. Revenue includes upfront licensing fees, milestone payments tied to development and regulatory achievements, and ongoing royalties on net sales.
- Product Development Partnerships: Joint development programs and co-development agreements with partners (e.g., San Raffaele Hospital, ProAgni) where Austrianova provides encapsulation technology and manufacturing capabilities in exchange for development funding and future commercial payments.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Austrianova product offering
Product offeringCore offering
Austrianova develops and commercializes proprietary cell encapsulation technologies — Cell-in-a-Box® for mammalian cells and Bac-in-a-Box® for bacteria and yeast — that protect living cells from immune rejection and environmental stress, and provides GMP-compliant cell banking (Master/Working Cell Bank), Fill and Finish, cell line development, and allogenic stem cell manufacturing services. Offerings are delivered to pharmaceutical, biotech, agriculture, aquaculture, food, and cosmeceutical clients via licensing agreements, contract manufacturing, and joint development partnerships.
Product overview
Austrianova is a biotechnology company offering cell encapsulation and manufacturing services through two core proprietary platforms: Cell-in-a-Box® for mammalian cell encapsulation and Bac-in-a-Box® for bacterial/yeast encapsulation. These platforms are supported by GMP4Cells services including cell banking, cell line development, and stem cell manufacturing. The company operates facilities in Singapore, Thailand, and Germany, providing B2B services to pharmaceutical and biotech partners for applications including cell therapy, probiotics, cancer treatment, and metabolic disease therapies.
Differentiator
Problem solved
Functional benefit
Brands
- Cell-in-a-Box®: Proprietary cell encapsulation technology for protecting living mammalian cells from immune rejection for therapeutic applications.
- Bac-in-a-Box®
- Pep-in-a-Box
- GMP4Cells
Products and services
- Cell-in-a-Box®
Quantifiable outcome
- Bac-in-a-Box provides 10,000x better acid protection than competing technologies
- +2 more outcomes
Companies that use Austrianova
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Austrianova technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Austrianova partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, minor and major.
- Klothea Bio Inc.coreExclusive worldwide license granted to Klothonova (the Austrianova-Avaí Bio JV) to develop, manufacture, and commercialize Klothea Bio's proprietary Klotho-producing cell line using Cell-in-a-Box® encapsulation technology. The agreement includes milestone payments tied to development and regulatory achievements and royalties on net sales.
- University of Veterinary Medicine, ViennaminorCollaborative research partner on encapsulated cell therapy for cancer. Published joint peer-reviewed study demonstrating long-term survival of encapsulated cells and metronomic ifosfamide activation in pancreatic cancer models (Life journal, 2023).
- Avaí Bio, Inc. (formerly Avant Technologies)core50/50 joint venture Klothonova established in September 2025 as a Nevada-based company focused on developing encapsulated cell-based α-Klotho anti-aging therapies. Austrianova contributes its Cell-in-a-Box® IP and manufacturing; Avaí Bio provides capital and resources. The JV secured an exclusive worldwide license from Klothea Bio in November 2025 for Klotho-producing cell lines. A GMP Master Cell Bank was completed in May 2026.
- ProAgnimajorLicensing and manufacturing agreement for development and commercialization of shelf-stable probiotic additives for cattle feed and other farm animals using Bac-in-a-Box® technology. Aims to reduce methane emissions and improve production efficiency in livestock. Austrianova provides encapsulation manufacturing; ProAgni provides bacterial strains active in the rumen.
- San Raffaele University and Research HospitalmajorJoint development program for multiple myeloma using Bac-in-a-Box® to deliver Prevotella melaninogenica bacteria to prevent progression from smouldering to aggressive disease. San Raffaele provides scientific expertise in immunology; Austrianova provides encapsulation technology for stomach acid protection and delivery.
- L'OrealminorExisting contract for Bac-in-a-Box® technology application in cosmetics extended during 2022.
- Kingen BiotechminorAlliance formed in 2022 as part of Austrianova's expanding partner network in the cell therapy/regenerative medicine space.
- Leave a Nest / Thailand Life Sciences ClusterminorAustrianova participates as a founder member of the Thailand Life Sciences Cluster and as a member of the Leave a Nest family, supporting connections in the Southeast Asian biotech ecosystem.
Scale indicators6 records
Recent moves8 records
Expansion highlights7 records
Austrianova competitors and assessment
Company assessmentDirect peers
- PharmaCyte Biotech: Clinical-stage oncology developer whose lead pancreatic cancer IND directly references Austrianova's Cell-in-a-Box® DMF. PharmaCyte is essentially a license-customer for Austrianova's encapsulation platform and the most direct downstream commercial proof point.
- Living Cell Technologies: Clinical-stage company developing DIABECELL encapsulated porcine islet cells for type 1 diabetes; a long-standing direct peer in the encapsulated living-cell therapy category, targeting overlapping indications to Cell-in-a-Box® metabolic programs.
- Sigilon Therapeutics: Develops encapsulated cell therapies (notably for type 1 diabetes and rare diseases) using proprietary Afibromer spheres — a direct functional analog to Cell-in-a-Box® in the immuno-protected cell therapy space.
- Betalin Therapeutics: Israeli biotech developing an engineered micro-pancreas using encapsulated islet cells for insulin-dependent diabetes; competes with Austrianova in the same encapsulated cell-therapy-for-metabolic-disease niche.
- Diatranz Otsuka Limited (DOL): New Zealand/Australia-based developer of encapsulated porcine islet cell therapy (DIABECELL) for type 1 diabetes; another direct encapsulation-therapeutics peer with GMP cell banking and clinical experience overlapping Austrianova's.
Broad incumbents
- Lonza Cell & Gene Technologies: Global CDMO incumbent with end-to-end cell and gene therapy manufacturing services. Lonza competes with Austrianova's GMP4Cells offering for outsourced cell banking and fill-finish contracts, but at much larger scale and broader scope.
- Catalent (cell therapy): Major CDMO with growing cell therapy manufacturing footprint and iPSC platform. Overlaps with Austrianova's GMP4Cells services for biotech partners seeking outsourced encapsulation-adjacent manufacturing capacity.
- Evotec (cell therapy CDMO): European-headquartered contract development and manufacturing organization with cell therapy capabilities. Competes for European and global GMP cell therapy manufacturing contracts that Austrianova also targets.
Others
- Cryoport Systems: Specialized cold-chain logistics provider for cell and gene therapies. Not a competitor but a complementary enabler of Austrianova's ambient-storage value proposition, often serving the same biotech customers.
Emerging players
- enGene: Clinical-stage gene therapy delivery company developing localized, immune-shielded therapeutics using its EGEN™ platform — an emerging encapsulation-adjacent delivery technology with overlapping therapeutic indications to Cell-in-a-Box®.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Austrianova social profiles
Digital presenceAustrianova compliance and trust
Trust signalCompliance1 record
Austrianova financial estimates
Financial estimateRevenue estimate
Valuation estimate
Austrianova leadership team
Management profileNumber of profiles
Profiles5 records
Austrianova subsidiaries and ownership
Company hierarchySubsidiaries4 records
Austrianova funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Austrianova M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Austrianova
What does Austrianova do?
Austrianova develops and commercializes proprietary cell encapsulation technologies — Cell-in-a-Box® for mammalian cells and Bac-in-a-Box® for bacteria and yeast — that protect living cells from immune rejection and environmental stress, and provides GMP-compliant cell banking (Master/Working Cell Bank), Fill and Finish, cell line development, and allogenic stem cell manufacturing services. Offerings are delivered to pharmaceutical, biotech, agriculture, aquaculture, food, and cosmeceutical clients via licensing agreements, contract manufacturing, and joint development partnerships.
Is Austrianova a public or private company?
Austrianova is a private company. It is classified as venture growth investor backed and is currently operating.
When was Austrianova founded?
Austrianova was founded in 2014. It employs 11 to 50 people.
Where is Austrianova based?
Austrianova is headquartered in Vienna, Austria, in the Europe region.
How does Austrianova make money?
Three revenue lines are on record. B2B Contract Manufacturing Services are the primary driver. The others are licensing and Technology Royalties and product Development Partnerships.
Who are Austrianova's main competitors?
Direct peers on record are PharmaCyte Biotech, Living Cell Technologies, Sigilon Therapeutics, Betalin Therapeutics and Diatranz Otsuka Limited (DOL). Broad incumbents are Lonza Cell & Gene Technologies, Catalent (cell therapy) and Evotec (cell therapy CDMO). Cryoport Systems is listed as an others. enGene is listed as an emerging player.
Does Austrianova have an API?
No public API is recorded for Austrianova.
What industry is Austrianova in?
Austrianova's product category is Cell Encapsulation & GMP Cell Manufacturing Services. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 325414 and its SIC code is 2836.